Kornimate/medical-research-clean huggingface dataset:
a comparison between the intubating laryngeal tube suction and the ambu auragain

Conditions: Difficult Intubation

Summary: the intubating laryngeal tube suction-disposable is a new version of the laryngeal tube-suction. it has a ventilator channel with a 13.5mm internal diameter, which enables the passage of an endotracheal tube with fiberoptic guidance. this study was designed to assess the time fiberoptic endotracheal intubation using ilts-d, in comparison with the and ambu® auragain™ in adult patients.

the intubating laryngeal tube suction-disposable is a new version of the laryngeal tube-suction. it has a ventilator channel with a 13.5mm internal diameter, which enables the passage of an endotracheal tube with fiberoptic guidance. this study was designed to assess the time of fiberoptic endotracheal intubation using ilts-d, in comparison with the and ambu® auragain™ in adult patients. detailed description: the intubating laryngeal tube suction-disposable (ilts-d) (vbm medizintechnik gmbh, sulz, germany) is a new updated version of the laryngeal tube-suction disposable (lts-d) it has a ventilator channel with a 13.5mm internal diameter, which enables the passage of an endotracheal tube (ett) with fiberoptic guidance. similarly as in to the lts-d, the ilts-d also has a separate channel for the purpose of placement of gastric tubes placement up to a size of 18 fr. the ilts-d comes in one size. according to the depth of insertion, this device is equivalent to size 4 for patients height 175 to 190 cm tall, or size 5 for patients taller than 190 cm. the ilts-d is provided by the manufacturer with a compatible 7.5 mm ett and with a plastic stabilizer for removal of the device. the current randomized study was designed to assess the success rate fiberoptic endotracheal intubation using ilts-d, in comparison with the and ambu® auragain™ in adult patients under general anesthesia

Eligibility criteria:
inclusion criteria: * american society anesthesiology i and ii exclusion criteria: * difficult intubation * cervical pathology * pregnancy

Keywords: fiberoptic supraglottic laryngeal tube intubation
treatment of rheumatoid arthritis with roxithromycin

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to evaluate the clinical efficacy, safety, and tolerability of roxithromycin in patients with rheumatoid arthritis.

this was 6-month, monocentre, randomized, double-blind, placebo-controlled study. we treated 100 patients with rheumatoid arthritis with either once-daily oral roxithromycin (300 mg) or daily oral placebo for 6 months. the primary efficacy variable was the percentage of patients who had a 20 percent improvement according to american college of rheumatology (acr) criteria (an acr 20 response) at six months. secondary outcome measures were 50 percent improvement and 70 percent improvement according to acr criteria (an acr 50 response and an acr 70 response, respectively).

Eligibility criteria:
inclusion criteria:ra according to the 1987 american rheumatism association criteria19, age between 18 and 70 years. patients were required to have had an inadequate response to one to four dmards (such as azathioprine, methotrexate, sulfasalazine, penicillamine, hydroxychloroquine, or oral or injectable gold); an inadequate response was defined as discontinuation of therapy because of lack of effect. if patients were receiving dmards, they were required to complete a dmard washout period that lasted at least 1 month before starting study drug treatment; no dmards were permitted during the study. patients who were receiving nonsteroidal antiinflammatory drugs, prednisone (at 10 mg daily or less), or both were eligible if the doses had been stable for at least four weeks before the study period and continued to be stable during the study period. patients were not allowed to receive intra-articular corticosteroids. patients had to have active disease at enrollment (before the dmard washout period), defined as 12 or more tender joints, 10 or more swollen joints, and at least one of the following: erythrocyte sedimentation rate(esr) of at least 28 mm/hr, c-reactive protein(crp) level greater than 2.0 mg/dl, or morning stiffness for at least 45 minutes. - exclusion criteria: * a negative pregnancy test result was required for non-menopausal female patients. in female patients of childbearing potential a urine pregnancy test was done at baseline and any pregnant women were excluded. other exclusion criteria included impaired hepatic enzyme tests, impaired renal function, chronic/recurrent infection (e.g., chronic bronchitis, recurrent sinusitis), other infections(e.g., borrelia burgdorferi, chlamydia trachomatis, ureaplasma) , history of adverse reactions to macrolides, roxithromycin, or similar antibiotics. a patient could be withdrawn from the trial at any time after enrollment for the following reasons: the patient's request, severe or life-threatening adverse event, or inadequate control of arthritis symptoms (\>50 percent increase in the total number of swollen or tender joints) necessitating an increase in the systemic corticosteroid dosage or reinstitution of therapy with disease-modifying antirheumatic drugs.

Keywords: roxithromycin,rheumatoid arthritis,macrolides
the effects of a structured hand exercise program on trigger finger: a randomized controlled trial

Conditions: Trigger Finger

Summary: to explore the effectiveness of a structured hand exercise program as a conservative treatment for trigger finger.


Eligibility criteria:
inclusion criteria: * adults with aged \> 18 years old who are diagnosed with trigger finger * the green classification grade 2 or grade 3 * pain (nprs) equal or more than 4/10, during active triggering exclusion criteria: * pediatric or congenital trigger finger * previously received physiotherapy, corticosteroid injection or surgery for trigger finger * hand trauma, local infection or using systemic steroids due to other diseases

Keywords: trigger finger tenosynovitis physiotherapy conservative treatment exercise
liver fibrosis and gut microbiota in patients with psoriasis vulgaris and rheumatoid arthritis on methotrexate

Conditions: Psoriasis Vulgaris; Rheumatoid Arthritis; Fibrosis, Liver

Summary: while methotrexate (mtx) remains a treatment of choice for patients with rheumatoid arthritis (ra), psoriasis (pso) and psoriatic arthritis (psa), long-term mtx use has been shown to be associated with liver fibrosis and cirrhosis in these patients. in addition, gut dysbiosis has been found to be associated with liver fibrosis and cirrhosis via the gut-liver axis, underscoring the potential role of gut microbiota and bacterial translocation in the pathogenesis of chronic liver diseases in these patients. in this study, we aim to assess the prevalence of advanced liver fibrosis or cirrhosis among these patients on mtx treatment compared to those without, using transient elastography. we also aim to identify the possible risk factor(s) for advanced liver fibrosis or cirrhosis among them. further, we aim to characterize the difference in fecal microbiota patterns among these three groups of patients. using a cross-sectional, prospective cohort design, this study will enroll approximately 600 eligible patients, including 300 patients with pso/psa and 300 patients with ra, to examine the following hypotheses: 1. patients on higher cumulative dose of mtx will have higher prevalence of advanced liver fibrosis or cirrhosis compared to those on lower cumulative dose of mtx; 2. patients with mtx use will have higher prevalence of advanced liver fibrosis or cirrhosis compared to those without mtx use; 3. the fecal microbiota composition will be different between patients with and without mtx treatment; and 4. the fecal microbiota composition will be different between patients with and without advanced fibrosis/cirrhosis while on mtx treatment.


Eligibility criteria:
inclusion criteria: * age between 18 to 85 years * have regular follow up in dermatology/ rheumatology clinics of queen mary hospital * diagnosed with pso/psa or ra * chinese ethnicity exclusion criteria: * age below 18 years or above 85 years * known decompensated cirrhosis * pregnancy or breastfeeding * unstable medical illness or active infection * unable to provide written consent * unable to adhere to the protocol * unable to read and/or write chinese language * on anticoagulant/ antiplatelet treatment * abnormal platelet count \<150 * known disease/condition with prolonged inr/bleeding tendency

Keywords: methotrexate microbiota
sintilimab combined with gemox ± ibi305 (bevacizumab biosimilar) versus gemox in advanced intrahepatic cholangiocarcinoma

Conditions: Intrahepatic Cholangiocarcinoma

Summary: a randomized controlled, phase ii clinical trial is designed to compare the safety and efficacy of sintilimab combined with gemox ± ibi305 and gemox as first-line therapy in advanced intrahepatic cholangiocarcinoma.


Eligibility criteria:
inclusion criteria: * written informed consent should be signed before implementing any trial-related procedures * male or female, 18 years old ≤ age ≤ 75 years old * histopathologically or cytologically diagnosed as locally advanced intrahepatic cholangiocarcinoma * no previous systemic treatment, more than 6 months after the end of postoperative adjuvant therapy was allowed * expected survival time \> 3 months * at least ≥ 1 measurable lesions per recist 1.1 * ecog ps scores 0-2 * sufficient organ and bone marrow function * urine or serum pregnancy test is negative exclusion criteria: * suffered from other malignant tumors in the past 5 years (except radical basal cell carcinoma of the skin squamous carcinoma of the skin and/or radical resected carcinoma in situ) * ampullary tumor * received treatment from other clinical trials within 4 weeks before the first dose * received any anti-pd-1 antibody, anti-pd-l1/l2 antibody, anti-ctla4 antibody, or other immunotherapy * suffered from severe cardiovascular disease within 12 months before enrollment, such as symptomatic coronary heart disease, congestive heart failure ≥ grade ii, uncontrolled arrhythmia, and myocardial infarction * uncontrollable pleural effusion, pericardial effusion or ascites * use steroids or other systemic immunosuppressive therapies 4 weeks before enrollment * allergic reactions to the drugs used in this study * hiv antibody positive, active hepatitis b or c (hbv, hcv) * known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation * other conditions that the investigator deems inappropriate for enrollment.

Keywords: intrahepatic cholangiocarcinoma first-line therapy sintilimab ibi305 gemox
mindfulness practice vs strength training on pain, kinesiophobia and function among sprinters

Conditions: Resistance Training; Patellofemoral Pain Syndrome; Kinesiophobia; Sprinters

Summary: the study is randomized and single-blinded. ethical approval is taken from ethical committee of riphah international university, lahore. participants who meet the inclusion criteria will be enrolled and allocated in group a \& b through sealed envelope method by non-probability convenient random sampling technique. subjects in group a will receive the strength training only. group b will receive the mindfulness-exercise in addition to the strength training protocol.

the objective of the study is to determine the effects of mindfulness practice with strength training on pain, kinesiophobia and function among sprinters with patellofemoral syndrome. the study is randomized and single-blinded. ethical approval is taken from ethical committee of riphah international university, lahore. participants who meet the inclusion criteria will be enrolled and allocated in group a \& b through sealed envelope method by non-probability convenient random sampling technique. subjects in group a will receive the strength training only. group b will receive the mindfulness-exercise in addition to the strength training protocol. usual pain, pain during stepping, and pain during running will be assessed using visual analog scales. functional limitations of the knee will be assessed using the knee outcome survey. fear of movement, pain catastrophizing, and coping strategies will be measured via the tampa scale for kinesiophobia, the pain catastrophizing scale, and the coping strategies questionnaire, respectively. for strength training we will use muscle-strengthening exercise questionnaire short form (mseq). these outcomes will be assessed at baseline and after 6 weeks the data will be analyzed by spss, version 25. statistical significance is p=0.05.

Eligibility criteria:
inclusion criteria: * males and female between the ages of 18 and 40 years, report running ≥2 times per week for \>45 minutes or a minimum weekly running distance of 10 km, present a history of insidious onset of signs and symptoms of pfp in 1 or both knees that was unrelated to trauma for at least 3 months before assessment, score \<85/100 on the activities of daily living scale and sports related of the knee outcome survey (kos-adls) exclusion criteria: * intra-articular condition, coexisting lower limb injury, history of patellar dislocation or knee surgery, osgood-schlatter or sinding- larsen-johansson syndrome

Keywords: mindfulness practice resistance training pain sprinters patellofemoral pain syndrome
outcomes of complete versus partial preservation of the sub-valvular apparatus in cases of mitral valve replacement

Conditions: Mitral Valve Replacement; Mitral Insufficiency

Summary: the purpose of this study is to evaluate the outcomes of complete (preservation of both anterior and posterior leaflets) versus partial (preservation of posterior leaflet only) preservation of subvalvular apparatus in cases of mitral valve replacement

after mitral valve replacement (mvr), sudden increases in afterload and disruption of the annular-chordal-papillary-left-ventricular wall causes left ventricular (lv) dysfunction in the early postoperative period. patients with lv dysfunction after mvr have a significantly lower 8-year survival rate compares with patients who did not have lv dysfunction papillary muscles play an important role in the left ventricular contraction by drawing the mitral ring toward the apex, thereby causing shortening of the long axis and spherity of the chamber contribute for better ejection of blood. preservation of papillary muscles and chordae tendineae in mvr reduces postoperative mortality, low cardiac output syndrome and improves haemodynamic function. partial preservation of the mitral apparatus through preservation of the posterior leaflet (mvr-p) has been proven to significantly reduce perioperative mortality. the importance of complete preservation of the mitral apparatus remains controversial, but it is hypothesized that complete preservation with preservation of both the anterior and posterior leaflets may contribute to superior postoperative hemodynamic function as compared to partial preservation. due to the increased technical complexity of preserving both leaflets, concerns about longer bypass and cross-clamp times, the need to undersize prostheses, and the possibility of left ventricular outflow tract (lvot) obstruction, the majority of cardiac surgeons currently prefer to preserve the posterior leaflet alone.

Eligibility criteria:
inclusion criteria: * - age between 18 and 60 years * rheumatic mitral disease indicated for mitral valve replacement * concomitant other valve disease exclusion criteria: * - patients who have undergone previous mitral valve surgery or other heart surgery. * patients with ischemic mitral disease. * emergency operation. * patients with significant comorbidities (severe pulmonary disease or end stage renal disease).
assessment of initial efficacy and safety of high intensity focused ultrasound 'exablate 4000 type 2' for blood brain barrier disruption in patients with alzheimer's disease

Conditions: Alzheimer Disease

Summary: the proposed study is to evaluate initial efficacy and safety of the bbb disruption with transcranial mri-guided focused ultrasound (exablate 4000 type 2.0) in patients with alzheimer's disease. this study iw designed as a prospective, single-site, single-aarm, nonrandomized study. assessments will be made before and three months after 2 sessions of bbb disruption with radiologic, nuclear medicine imaging and neurophysiological examinations. relative safety will be evaluated using a common description of significant clinical complications for patients treated in this study.


Eligibility criteria:
inclusion criteria: * age between 50 and 85 years, inclusive. * total score of 23 or less on the korean version of mini mental state exam (k-mmse) * fbb (18f-florbetaben)-pet test result positive * fdb (18f-fluorodeoxyglucose)-pet test results suspected of alzheimer disease-induced neurodegeneration * mild cognitive impairment or dementia caused by alzheimer's disease * a participant who has been given a drug at a stable dose for at least three months to improve symptoms of alzheimer's disease * able to communicate during the exablate bbb disruption procedure * able and willing to give informed consent * able to attend all study visits exclusion criteria: * cga-npi (caregiver-administrated neuropsychiatry inventory) severity score of more than 2 points for any of "delusion", "hallucination" or "agitation/aggression" * known sensitivity/allergy or contraindications to mri contrast agent(gadovist®) or the ultrasound contrast agent (definity®) * contraindications to mri such as non-mri compatible implanted devices. * any of the following items in mri 1. severe ischemic changes 2. active or chronic infection/inflammation 3. acute or chronic hemorrhage 4. tumor/space occupying lesion 5. meningeal enhancement 6. intracranial hypotension * more than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp * active seizure disorder or epilepsy (seizures despite medical treatment) * history of a bleeding disorder, coagulopathy * cardiac disease or unstable hemodynamics * severely impaired renal function with estimated glomerular filtration rate \<30 ml/min/1.73m2 * severe brain atrophy * hiv (human immunodeficiency virus) positive, who have a high probability of developing hiv encephalitis due to the influx of hiv in to the brain parenchyma * subjects with evidence of cranial or systemic infection * a homozygosity of apolipoprotein e allele (apoe4) known to have a thin blood-brain barrier * positive pregnancy test (women of childbearing potential) * a participant in other clinical trials or have experience in other clinical trials within 90 days from the screening date
blood flow and bone density in healthy adult women

Conditions: Bone Loss; Hypotensive; Lower Limb Fluid Pooling

Summary: this project will test the efficacy of using a non-invasive neuromuscular stimulation on the plantar surface of the feet to prevent and/ or reverse bone loss in a sample of healthy adult women.

women between the ages of 30 and 60 years of age who work in positions that require them to be seated at desks for a large portion of each day, are capable of following the protocol for one year, have a t-score \>- 2.5 (do not have osteoporosis), and respond to plantar stimulation will be asked to participate. women will be excluded who are receiving medications for osteoporosis, taking hormone replacement therapy, taking steroids (either oral or inhaled), have metal implants in the tibia, hip and spine that interfere with dexa (bone density) scanning, are professional or semi-professional athletes, have hyperparathyroidism, have a history of pulmonary embolism, deep vein thrombosis, peripheral vascular disease or varicose veins, have a body mass index greater than 40 kg/m2, have any type of neuromuscular disease, or are pregnant . once the inclusion and exclusion criteria are met, 45 subjects will be randomized into 3 groups including 1) a group of 15 subjects who will use the device (stimulation) for up to 4 hours a day, 2) a group of 15 subjects that will use the device for up to 8 hours a day, and 3) a control group who will not use the device. subjects in the two treatment groups will be asked to place their feet on a mechanical device that will deliver a slight vibration while they are seated at work. vibrations between 30-60 hz has been shown to stimulate the meissner's corpuscles which in turn stimulate contraction of the deep muscles of the calves. this contraction has been shown to increase venous and lymphatic return from the lower extremities thus improve bone metabolism. bone density readings and venous circulation will be measured at the onset of this research and will be repeated after 12 months of using the device.

Eligibility criteria:
inclusion criteria: * healthy women 30 - 60 years old * work in seated positions exclusion criteria: * weigh more than 350 pounds * pregnant or plan to become pregnant * professional athlete * currently on hormone replacement therapy * currently taking medication for osteoporosis * currently on corticosteroids * metal implants in tibia hip spine forearm * diagnosed with hyperparathyroidism * diagnosed with neuromuscular disease * pulmonary embolism * deep vein thrombosis * peripheral vascular disease * medications for hypertension

Keywords: osteoporosis sarcopenia calf muscle pump venous insufficiency dexa soleus muscle apg
administering a parent-based pilot intervention for reducing anxiety in children with asd and anxiety

Conditions: ASD, Anxiety

Summary: we are implementing the space program, an evidence-based protocol that has been proven to be efficent in childhood anxiety disorders and ocd (lebowitz, 2013; lebowitz, omer, hermes \& scahill, 2014), in a new population of children with asd and anxiety. the intervention aims to reduce family accommodation of the child's anxiety symptoms. the program contains 12 weekly 1-hour sessions with the parents. we will examine the impact of the intervention on family accommodation, asd and anxiety symptomology, as well as parent and child satisfaction from the intervention, using the attached measures.

participants are parents of children with asd and anxiety between the ages of 6-10. we will recruit 30 families. recruitment takes place through social media, the autism center of hebrew university, lab contacts and community partnerships. participants are parents of young children between the ages of 6-10, where the child has a recognized diagnosis of asd by ministry of health, social security or ministry of education, average (or above) cognition as per parent report and communication as measured by abas, and anxiety as measured by scared. parents of children who have other relevant neurological or medical conditions will be excluded. participants will be asked to provide a copy of the latest diagnosis prior to participation. measures (attached) will be administered prior to the intervention, at the conclusion and again 2 months later. participants will complete questionnaires online (qualtrics). treatment sessions will be held on zoom and certain sessions will be taped for supervision purposes. the program is designed to reduce child anxiety symptoms, parent stress and family accommodation. parents are likely to gain important skills and experience an increase in feelings of self-efficacy. the space program is parent-based and is applicable in cases where children are not cooperative, and if proven to be effective in the asd population, could serve not only as an alternative treatment but also as a primary intervention in the context of asd..

Eligibility criteria:
inclusion criteria asd anxiety symptoms exclusion criteria: * anxiety treatment
efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors

Conditions: Pancreatic Neuroendocrine Tumors

Summary: the purpose of the study is to evaluate the effect of sunitinib on the clinical benefit response rate.


Eligibility criteria:
inclusion criteria: * patients must have advanced (unresectable or metastatic) biopsy-proven pancreatic net (neuroendocrine tumor) exclusion criteria: * patients with poorly differentiated neuroendocrine cancer are not eligible

Keywords: neuroendocrine tumors